To explore metabolomic and inflammatory signatures associated with the biochemical response to levothyroxine (LT4) treatment in pediatric patients with congenital hypothyroidism (CH).
Approach:
Study Design: A prospective longitudinal study involving 11 pediatric CH patients, with plasma samples collected at diagnosis (Pre Tx) and after achieving biochemical euthyroidism (Post Tx).
Metabolomic Profiling: Conducted using tandem mass spectrometry to identify metabolic changes.
Inflammatory Assessment: Measured plasma concentrations of tumor necrosis factor-alpha (TNF-α) and interleukin 10 (IL-10).
Nutritional Evaluation: Assessed nutritional status through length-for-age Z-scores.
Key Findings:
Nine metabolites discriminated between Pre Tx and Post Tx samples, indicating metabolic changes.
Notable changes involved sphingolipid metabolism, with reduced ceramides and hexosylceramides, and increased sphingomyelins.
Circulating TNF-α and IL-10 levels were elevated at diagnosis and remained high post-treatment, showing a decreasing trend but no statistically significant differences.
Post Tx group showed a modest increase in length-for-age Z-score.
Interpretation:
The changes in circulating sphingolipids suggest metabolic adaptations following LT4 therapy, highlighting the potential of metabolomic profiling in understanding treatment responses in CH.
Limitations:
Small sample size of 11 patients may limit generalizability.
No statistically significant differences in inflammatory markers between time points.
Conclusion:
LT4 therapy in CH pediatric patients is associated with changes in sphingolipid metabolism.
by Marcela Vela-Amieva, Isabel Ibarra-González, Raúl Calzada León, María de la Luz Ruiz-Reyes, María Eugenia Constantini, Sara Guillén-López, Lizbeth López-Mejía, Michelle Citlalli Luna-Nequiz, Rosa Itzel Carrillo-Nieto, Cynthia Fernández-Lainez
Researchers found larger biological age gaps in more recent birth cohorts and observed associations with higher risk of several cancers diagnosed before age 55.
